Profits to Flow for Period-Stopping Drug
Joyce, Zanna, Herizons
[Graph Not Transcribed]
The first continuous-use oral contraceptive to be marketed specifically as a method to drastically reduce women's menstrual cycles is expected to be on the North American market as early as this Summer.
Currently under review by the US Food and Drug Administration. Seasonale, developed by Barr Laboratories, would reduce a woman's ovulation and menstruation cycles from an average of 12 a year to four. The estrogen and progestin content is comparable to standard oral contraceptives, but the hormones have a lower cumulative dosage. Normally, oral contraceptives reduce the growth of the lining in the uterus; Seasonale is designed to suppress it …
The rest of this article is only available to active members of Questia
Sign up now for a free, 1-day trial and receive full access to:
- Questia's entire collection
- Automatic bibliography creation
- More helpful research tools like notes, citations, and highlights
- Ad-free environment
Already a member? Log in now.
Questia, a part of Gale, Cengage Learning. www.questia.com
Publication information:
Article title: Profits to Flow for Period-Stopping Drug.
Contributors: Joyce, Zanna - Author.
Magazine title: Herizons.
Volume: 17.
Issue: 1
Publication date: Summer 2003.
Page number: 11.
© 2008 Herizons Magazine, Inc.
Provided by ProQuest LLC. All Rights Reserved.
This material is protected by copyright and, with the exception of fair use, may not be further copied, distributed or transmitted in any form or by any means.
One moment ...
- Georgia
- Arial
- Times New Roman
- Verdana
- Courier/monospaced
Reset